Bromfenac (sodium hydrate)

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium hydrate can be used in ocular inflammation research[1].

Product Specifications

CAS Number

[120638-55-3]

Product Name Alternative

Bromfenac (monosodium salt sesquihydrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Bromfenac-sodium-hydrate.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mL

Smiles

O=C(O[Na])CC1=CC=CC(C(C2=CC=C(Br)C=C2)=O)=C1N.[1.5H2O]

Molecular Formula

C15H14BrNNaO4.5

Molecular Weight

383.17

Precautions

H302, H315, H319, H335

References & Citations

[1]Tetsuo Kida, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9 (5) :e96481.|[2]Xiaobo Zhang, et al. Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. Bioact Mater. 2021 Jul 23;9:343-357.|[3]Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25 (1-2) : 77-85.|[4]Kaevalin Lekhanont, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007 Feb;23 (1) :27-34.